Skip to main content

Table 2 Secondary preventive cardiovascular prescription medication after myocardial infarction in patients with type 1 diabetes and matched controls without any type of diabetes

From: Long-term cardiovascular prognosis of patients with type 1 diabetes after myocardial infarction

 

Type 1 Diabetes

No Diabetes

 
 

n = 1403

n = 1403

OR (95% CI)

P value

ACEi or ARB

72.0%

66.2%

1.32 (1.12–1.56)

0.001

Aldosterone antagonist

5.7%

4.6%

1.24 (0.89–1.74)

0.204

Beta-blocker

85.2%

82.8%

1.11 (0.90–1.27)

0.318

Oral anticoagulant

11.7%

13.7%

0.82 (0.65–1.04)

0.101

P2Y12 inhibitor

69.4%

64.9%

1.25 (1.06–1.48)

0.008

Statin

81.8%

82.7%

0.94 (0.77–1.15)

0.540

  1. Controls were matched with a separate propensity score including sex, age, all co-morbidities listed in Table 1, revascularization by PCI or CABG, ST-elevation, year of index MI, and treating hospital (university versus non-university)
  2. ACEi angiotensin-converting-enzyme inhibitor, ADP adenosine diphosphate, ARB angiotensin receptor blocker, OR odds ratio, CI confidence interval
Back to article page